ASNC MiBG Letter
AdreView (lobenguane I 123 Injection) is a radiopharmaceutical agent for gamma-scintigraphy with a cardiac indication for scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart-to-mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) Class II or Class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, AdreView may be used to help identify patients with lower one-and two-year mortality risks, as indicated by and H/M ratio ≥ 1.6.
Currently, many payers are denying claims for MiBG. The letter attached urges payers to consider the medical necessity of each claim rather than denying payment across the board. In addition, ASNC has convened a multi-specialty writing committee that is working to develop a model coverage policy which will be useful in future conversations between physicians and payers.
To download and print the letter, click here.